Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: Role of inflammation in cancer-related anemia

Blood

Volumn 106, Issue 1, 2005, Pages 362-367

  Macciò, Antonio ^a   Madeddu, Clelia ^b   Massa, Daniela ^b   Mudu, Maria C ^b   Lusso, Maria R ^b   Gramignano, Giulia ^b   Serpe, Roberto ^b   Melis, Gian Benedetto ^b   Mantovani, Giovanni ^b  

^a Sirai Hospital   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; GLUTATHIONE PEROXIDASE; HEMOGLOBIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BODY HEIGHT; BODY WEIGHT; CANCER STAGING; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; OXIDATIVE STRESS; PERFORMANCE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; REGRESSION ANALYSIS;

EID: 22044438662     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-01-0160     Document Type: Article

References (46)

1. Obermair A, Handisurya A, Kaider A, et al. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. Cancer. 1998;15:726-731.
2. Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol. 2001;28:1-6.
3. Nowrousian MR, Kasper C, Oberhoff C. Pathophysiology of cancer-related anemia. In: Smythe J, ed. RHu Erythropoietin in Cancer Supportive Treatment. New York, NY: Marcel Dekker; 1996:13-34.
4. Spivak JK. The blood in systemic disorders. Lancet. 2000;355:1707-1712.
5. Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis. 1997;25:888-895.
6. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341:1986-1995.
7. Erslev AJ. Anemia of chronic disease. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams Hematology. New York, NY: McGraw-Hill Professionals: 2000:481-488.
8. Mantovani G, Maccio A, Madeddu C, et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer. 2002;98:84-91.
9. Mantovani G, Maccio A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med. 2000;78:554-561.
10. Mantovani G, Maccio A, Madeddu C, et al. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med. 2001;79:406-414.
11. Mantovani G, Maccio A, Pisano M, et al. Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int J Cancer. 1997;71:724-731.
12. Maccio A, Lai P, Santona MC, et al. High serum levels of soluble IL-2 receptor, cytokines, and C-reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998;69:248-252.
13. Aleman MR, Santolaria F, Batista N, et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine. 2002;19:21-26.
14. Means RT Jr. The anemia of infection. Baillieres Best Pract Res Clin Haematol. 2000;13:151-162.
15. Weinstein DA, Roy CN, Fleming MD, et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002;100:3776-3781.
16. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
17. Alberti A, Bolognini L, Macciantelli D, et al. The radical cation of N, N-Diethyl-para-Phenylendiamine: a possible indicator of oxidative stress in biological samples. Res Chem Intermed. 2000;26:253-267.
18. Cornelli U, Terranova R, Luca S, et al. Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr. 2001;131:3208-3211.
19. Means RT. Hepcidin and anaemia. Blood Rev. 2004;18:219-225.
20. van der Zee AG, de Cuyper EM, Limburg PC, et al. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer. 1995;75:1004-1009.
21. Ershler WB. Biological interaction of aging and anemia: a focus on cytokines. J Am Geriatr Soc. 2003;51:S18-S21.
22. Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest. 2004;113:1251-1253.
23. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-1276.
24. Nemeth E, Valore EV, Territo M, et al. Hepcidin: a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101: 2461-2463.
25. Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol. 2004;11:251-254.
26. Deicher R, Horl WH. Hepcidin: a molecular link between inflammation and anaemia. Nephrol Dial Transplant. 2004;19:521-524.
27. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood. Prepublished on October 12, 2004, as DOI 10.1182/blood-2004-08- 3375.
28. (Now available as Blood. 2005;105:1797-1802).
29. Nash MA, Ferrandina G, Gordinier M, et al. The role of cytokines in both the normal and the malignant ovary. Endocr Relat Cancer. 1999;6:93-107.
30. Berek JS, Chung C, Kald K, et al. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991;164:1038-1042.
31. Scambia G, Testa U, Benedetti Panici P, et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71:354-356.
32. Mantovani G, Maccio A, Versace R, et al. Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC. J Mol Med. 1995;73:409-416.
33. Means RT Jr. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells. 1995;13:32-37.
34. Kuzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92:1684-1688.
35. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients whit the anemia of cancer. N Engl J Med. 1990;322:1689-1692.
36. Alvarez-Hernandez X, Liceaga J, McKay IC, et al. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest. 1989;61:319-322.
37. Rogers JT Ferritin translation by interleukin-1 and interleukin-6: the role of sequences upstream of the start codons of the heavy and light subunit genes. Blood. 1996;87:2525-2537.
38. Konijn AM, Carmel N, Levy R, et al. Ferritin synthesis in inflammation: mechanisms of increased ferritin synthesis. Br J Hematol. 1981;49:361-370.
39. Denz H, Huber P, Landmann R, et al. Association between the activation of macrophages, changes of iron metabolism and the degree of anemia in patients with malignant disorders. Eur J Haematol. 1992;48:244-248.
40. Mantovani G, Macciò A, Madeddu C, et al. The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res. 2003;37:213-223.
41. Numcke I, Schneider B, Fandrey J, et al. Effect of pro- and antioxidative compounds on renal production of erythropoietin. Endocrinology. 1999;140:641-645.
42. Takeda A, Toda T, Shinohara S, et al. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin. Am J Kidney Dis. 2002;40:104-109.
43. Gainsford T, Willson TA, Metcalf D, et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci USA. 1996;93:14564-14568.
44. Munstedt K, Kovacic M, Zygmunt M, et al. Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol. 2003;23:837-843.
45. Tchekmedian NS. Anemia in cancer patients: significance, epidemiology and current therapy. Oncology. 2002;16:17-24.
46. Stenvinkel P. Anaemia and inflammation: what are the implications for the nephrologist? Nephrol Dial Transplant. 2003;18:7-22.